Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vermillion Board of Directors Nominates Paul R. Sohmer for Company Director

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Nominee brings extensive management, governance and clinical diagnostics experience.

Vermillion, Inc. has announced that its board of directors has unanimously nominated Paul R. Sohmer, M.D. for election as a director at the upcoming annual meeting of stockholders.

Dr. Sohmer was recommended to serve on the board as an independent investor representative by a Vermillion stockholder with long-term holdings of approximately 5% of the company's outstanding common stock.

After consideration of Dr. Sohmer's background and qualifications, the board of directors determined he is an exceptionally qualified candidate.

"Paul's nomination is a perfect fit to our in vitro diagnostic business with his 27 years of experience in public and private growth companies focused on laboratory services, medical devices, and biotechnology," said James Burns, Vermillion's chairman.

Dr. Sohmer would bring a broad range of clinical diagnostics leadership experience to the board, having previously provided direction and oversight to numerous public and privately held companies engaged in the development, manufacture, marketing and sale of in vitro diagnostic reagents and instruments, as well as the delivery of hospital-based and esoteric reference laboratory services.

He also possesses a wealth of experience developing companies and increasing shareholder value via leveraging the capital markets, developing strategic alternatives, and leading merger and acquisition transactions.

Dr. Sohmer is currently president and CEO of Viracor-IBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology and infectious disease testing.

Prior to Viracor-IBT, he served as CEO of Orthocon, Inc., a developer, manufacturer and marketer of implantable medical products.

He also previously served as interim CEO of Cylex, Inc. and CEO of Pathway Diagnostics Ltd., during which time he also served on the board of RadPharm, Inc. and as chairman of Molecular Biometrics, Inc.

Earlier in his career he served as president and CEO of NASDAQ-listed Neuromedical Systems, Inc., until its acquisition by TriPath Imaging, Inc. a NASDAQ-listed cancer diagnostics company that developed and commercialized molecular diagnostic products for cervical, breast, ovarian and prostate cancers. He served TriPath as its chairman, president and CEO until it was purchased by Becton, Dickinson and Company, a leading global medical technology company.

Prior to Neuromedical Systems, he served as president and CEO of Genetrix, Inc., a genetic testing lab, until the company was acquired by Genzyme Corporation.

Before Genetrix, Dr. Sohmer was president and CEO of Pathology Institute, Inc., where he led the first commercial introduction of polymerase chain reaction for diagnosis of HIV and founded the Chiron Reference Laboratory.

Dr. Sohmer received his B.A. from Northwestern University and M.D. from the Chicago Medical School. He was named the Ernst and Young Carolinas Life Sciences Entrepreneur of the Year in 2005.

If elected, Dr. Sohmer would succeed current board member John F. Hamilton who has not been nominated for re-election at this meeting. "We thank John for his six years of exceptional service to the board," said Burns, "and we wish him continued success in his other endeavors."

Dr. Sohmer's election to the board, along with Vermillion's other nominee, would maintain the total number of directors on the board at seven, with six serving independently.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Friday, March 21, 2014
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Company will next pursue a national price for its OVA1 test in 2014.
Saturday, March 08, 2014
Vermillion to Present at the 26th Annual ROTH Conference
Company to present at the conference on March 11, 2014.
Thursday, March 06, 2014
Vermillion to Present at Leerink Global Healthcare Conference
Conference to be held at the Waldorf Astoria Hotel from February 12-13, 2014.
Tuesday, February 04, 2014
Vermillion Completes $17.6 Million Warrant Exercise
Proceeds from the warrant exercise will be used to increase test sales for OVA1.
Friday, December 20, 2013
Vermillion Reports Results of 2013 Annual Meeting
Company has approved the reappointment of Peter S. Roddy.
Friday, December 20, 2013
Vermillion Appoints SVP of Sales and Marketing and Chief Commercial Officer
Appointment of Marian E. Sacco as senior vice president of sales and marketing.
Friday, December 20, 2013
Vermillion Board of Directors Elects James T. LaFrance as Chairman
LaFrance has been appointed a member of Company’s board on December 12, 2013.
Monday, December 16, 2013
Vermillion Reports Third Quarter 2013 Results
Company reports Q3 2013 financial results and key developments.
Friday, November 15, 2013
American Journal of Obstetrics & Gynecology Publishes New Clinical Study of OVA1 Test
Significantly superior early-stage sensitivity shown versus CA125, modified ACOG guidelines or overall clinical assessment in premenopausal and postmenopausal women planning surgery.
Thursday, November 14, 2013
Vermillion Appoints Dr. Eric Varma to its Board of Directors
Dr. Varma is currently a partner at Oracle Investment Management.
Tuesday, September 17, 2013
Vermillion's OVA1 Receives New Statement by SGO
OVA1® has received new statement on clinical validation and medical use.
Tuesday, July 16, 2013
Vermillion Appoints President and Chief Executive Officer
Appointment of Thomas McLain effective March 18, 2013.
Thursday, July 04, 2013
Vermillion Appoints Bruce A. Huebner to Chairman of the Board
Shareholders to vote on approval of expanded stock incentive plan at upcoming annual meeting.
Friday, June 28, 2013
Vermillion Announces Closing of Equity Financing
Company to increase the number of directors of the Company from six to eight persons.
Thursday, May 16, 2013
Scientific News
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Antibiotic Resistance Mechanism Continues to Spread
A recently discovered genetic mechanism allowing bacteria to develop and transfer resistance to colistin, one of the last-resort antibiotics, has been present in many countries across the world for more than a decade, according to late-breaking data presented at ECCMID.
Promising New Method Inhibits TB-Causing Bacteria
Researchers at UQ and UC San Francisco have found a new way to inhibit the growth of the bacterium that causes tuberculosis.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!